Unicycive Therapeutics, Inc. (UNCY)

Market Cap	184.76M +155.3%
Revenue (ttm)	n/a
Net Income	-39.95M
EPS	-2.11
Shares Out	26.70M
PE Ratio	n/a
Forward PE	3.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,201,319
Open	7.41
Previous Close	7.43
Day's Range	6.86 - 7.41
52-Week Range	3.71 - 11.00
Beta	1.73
Analysts	Strong Buy
Price Target	41.30 (+496.82%)
Earnings Date	May 12, 2026

About UNCY

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 13, 2021
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: UNCY
• Website: https://unicycive.com

Analyst Summary

According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $41.3, which is an increase of 496.82% from the latest price.

Price Target

$41.3

(496.82% upside)

Analyst Consensus: Strong Buy